Dideoxycytidine for AIDS
HHS is seeking an industry sponsor to collaborate in the preclinical and clinical development of the antiviral for treatment of AIDS. In the Oct. 14 Federal Register, HHS reported that National Cancer Institute scientists have shown dideoxycytidine "is effective in inhibiting in vitro growth of HTLV-III, the etiologic agent of AIDS." The agency said the industry sponsor will be granted an exclusive royalty-bearing license, while the U.S. government will receive "reasonable royalties".
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.